Fifty-eight percent of post-mpox participants had at least 1 persistent sequela; most of these were appearance-related.

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Investigators assessed the prevalence of adverse pregnancy outcomes among women with spondyloarthritis vs a matched ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

HealthDay News — With the end of federal health insurance subsidies, President Donald Trump has floated a new plan aimed at ...

HealthDay News — Between 2019 and 2024, there was a decline in skilled nursing facility (SNF) capacity, with a decrease in ...

Early childhood is a key period for immune maturation, yet evidence linking early animal exposures with the development of ...

HealthDay News — The count and rate of emergency department (ED) visits for alcohol-specific diagnoses increased from ...

Credit: Getty Images Prioritizing nonpharmacologic strategies, enhancing staff training, and distinguishing Delirium Superimposed on Dementia (DSD) are vital to improving outcomes for hospitalized ...

FDA grants Breakthrough Therapy designation to ianalumab for Sjögren disease after the monoclonal antibody showed significant disease improvement.

Federal funding for mental health and addiction treatment programs will continue after the Trump administration abruptly reversed a plan to end nearly $2 billio ...